2076975 2077203
최종편집 2024-02-23 22:49 (금)
MSD's Von Hippel-Lindau disease treatment Welireg receives approval in Korea
상태바
MSD's Von Hippel-Lindau disease treatment Welireg receives approval in Korea
  • Hyeokgi Lee, Newsmp
  • 승인 2023.05.30 16:07
  • 댓글 0
이 기사를 공유합니다

[Newsmp] Welireg (belzutifan) by MSD Korea received approval from the Ministry of Food and Drug Safety on the 23rd.

Welireg has been authorized as a therapy for von Hippel-Lindau (VHL) disease, a condition characterized by the development of multiple tumors, by inhibiting cancer-promoting factor (GIF-2a) associated with angiogenesis, cell proliferation, and tumor growth.

This can help slow down tumor progression and decrease the risk of repetitive tumor resection surgeries in patients with Von Hippel-Lindau disease, where the cancer-inducing factor is not regulated due to mutations in tumor suppressor genes.

The Ministry of Food and Drug Safety explained that Welireg is used in the treatment of non-surgical cases of renal cell carcinoma, central nervous system hemangioblastoma, and pancreatic neuroendocrine tumors in adult patients with von Hippel-Lindau disease.


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.